Five Prime Therapeutics (NASDAQ:FPRX) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

A number of other equities analysts have also recently weighed in on the stock. Wedbush raised shares of Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Thursday, January 17th. ValuEngine cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. Finally, Zacks Investment Research raised shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company’s stock. Five Prime Therapeutics has a consensus rating of “Buy” and a consensus price target of $28.33.

Five Prime Therapeutics stock opened at $10.53 on Tuesday. Five Prime Therapeutics has a 1-year low of $7.84 and a 1-year high of $22.75. The company has a market capitalization of $396.86 million, a PE ratio of -1.96 and a beta of 3.12.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The firm had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $7.45 million. Five Prime Therapeutics had a negative net margin of 221.67% and a negative return on equity of 41.52%. As a group, sell-side analysts forecast that Five Prime Therapeutics will post -4.3 earnings per share for the current year.

Several large investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. lifted its holdings in Five Prime Therapeutics by 14.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 175,895 shares of the biotechnology company’s stock worth $2,781,000 after buying an additional 22,572 shares in the last quarter. BlackRock Inc. lifted its holdings in Five Prime Therapeutics by 7.9% during the 2nd quarter. BlackRock Inc. now owns 2,863,520 shares of the biotechnology company’s stock worth $45,271,000 after buying an additional 210,031 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Five Prime Therapeutics by 14.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,189,654 shares of the biotechnology company’s stock worth $18,808,000 after buying an additional 147,904 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in Five Prime Therapeutics by 48.7% during the 2nd quarter. MetLife Investment Advisors LLC now owns 19,957 shares of the biotechnology company’s stock worth $316,000 after buying an additional 6,535 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Five Prime Therapeutics by 6.7% during the 2nd quarter. Northern Trust Corp now owns 394,878 shares of the biotechnology company’s stock worth $6,243,000 after buying an additional 24,838 shares in the last quarter. 85.95% of the stock is owned by hedge funds and other institutional investors.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Read More: Why is the price-sales ratio important?

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.